VYGR Voyager Therapeutics Inc

Price (delayed)

$8.77

Market cap

$477.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$333.95M

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation ...

Highlights
VYGR's equity has surged by 57% year-on-year and by 44% since the previous quarter
Voyager Therapeutics's quick ratio has plunged by 63% YoY but it has increased by 14% from the previous quarter
Voyager Therapeutics's EPS has plunged by 103% YoY and by 102% from the previous quarter
Voyager Therapeutics's net income has shrunk by 103% YoY and by 102% QoQ

Key stats

What are the main financial stats of VYGR
Market
Shares outstanding
54.39M
Market cap
$477.03M
Enterprise value
$333.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.4
Price to sales (P/S)
4.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.81
Earnings
Revenue
$119.04M
EBIT
-$14.05M
EBITDA
-$9.49M
Free cash flow
$8.23M
Per share
EPS
-$0.07
Free cash flow per share
$0.14
Book value per share
$6.28
Revenue per share
$2.08
TBVPS
$8.22
Balance sheet
Total assets
$469.59M
Total liabilities
$128.71M
Debt
$0
Equity
$340.89M
Working capital
$336.58M
Liquidity
Debt to equity
0
Current ratio
5.64
Quick ratio
5.55
Net debt/EBITDA
15.08
Margins
EBITDA margin
-8%
Gross margin
100%
Net margin
-2.6%
Operating margin
-14.3%
Efficiency
Return on assets
-0.9%
Return on equity
-1.3%
Return on invested capital
-8.4%
Return on capital employed
-3.5%
Return on sales
-11.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VYGR stock price

How has the Voyager Therapeutics stock price performed over time
Intraday
-1.9%
1 week
16.62%
1 month
1.15%
1 year
-9.77%
YTD
3.91%
QTD
10.87%

Financial performance

How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$119.04M
Gross profit
$119.04M
Operating income
-$17.05M
Net income
-$3.04M
Gross margin
100%
Net margin
-2.6%
The operating margin has plunged by 129% from the previous quarter and by 129% YoY
The operating income has dropped by 118% year-on-year and by 114% since the previous quarter
The company's net margin has shrunk by 105% YoY and by 105% QoQ
Voyager Therapeutics's net income has shrunk by 103% YoY and by 102% QoQ

Growth

What is Voyager Therapeutics's growth rate over time

Valuation

What is Voyager Therapeutics stock price valuation
P/E
N/A
P/B
1.4
P/S
4.21
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.81
Voyager Therapeutics's EPS has plunged by 103% YoY and by 102% from the previous quarter
VYGR's equity has surged by 57% year-on-year and by 44% since the previous quarter
VYGR's price to book (P/B) is 50% lower than its 5-year quarterly average of 2.8 and 26% lower than its last 4 quarters average of 1.9
VYGR's price to sales (P/S) is 56% more than its last 4 quarters average of 2.7 and 8% more than its 5-year quarterly average of 3.9
The revenue has dropped by 52% since the previous quarter and by 38% year-on-year

Efficiency

How efficient is Voyager Therapeutics business performance
Voyager Therapeutics's ROS has plunged by 124% from the previous quarter and by 123% YoY
Voyager Therapeutics's ROIC has plunged by 108% from the previous quarter and by 101% YoY
Voyager Therapeutics's return on assets has shrunk by 102% QoQ and by 102% YoY
VYGR's return on equity has dropped by 102% since the previous quarter and by 101% year-on-year

Dividends

What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VYGR.

Financial health

How did Voyager Therapeutics financials performed over time
VYGR's current ratio has dropped by 63% year-on-year but it is up by 14% since the previous quarter
Voyager Therapeutics's quick ratio has plunged by 63% YoY but it has increased by 14% from the previous quarter
The company's debt is 100% lower than its equity
VYGR's equity has surged by 57% year-on-year and by 44% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.